학술논문

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models
Document Type
Academic Journal
Source
Journal of Clinical Investigation. February, 2020, Vol. 130 Issue 2, p699, 16 p.
Subject
Canada
Language
English
ISSN
0021-9738
Abstract
HSP27 is highly expressed in, and supports oncogene addiction of, many cancers. HSP27 phosphorylation is a limiting step for activation of this protein and a target for inhibition, but its highly disordered structure challenges rational structure-guided drug discovery. We performed multistep biochemical, structural, and computational experiments to define a spherical 24-monomer complex composed of 12 HSP27 dimers with a phosphorylation pocket flanked by serine residues between their N-terminal domains. Ivermectin directly binds this pocket to inhibit MAPKAP2-mediated HSP27 phosphorylation and depolymerization, thereby blocking HSP27-regulated survival signaling and client-oncoprotein interactions. Ivermectin potentiated activity of anti-androgen receptor and anti-EGFR drugs in prostate and EGFR/HER2-driven tumor models, respectively, identifying a repurposing approach for cotargeting stress-adaptive responses to overcome resistance to inhibitors of oncogenic pathway signaling.
Introduction Small heat shock proteins (sHSPs) are ATP-independent molecular chaperones characterized by a conserved [alpha]-crystallin domain located between a highly flexible, variable C-terminal region and a poorly conserved, disorganized N-terminal [...]